Lower costs lift Richter earnings
First-quarter net income of Hungarian drugmaker Gedeon Richter rose 61% to HUF 15 bln from the same period a year earlier as costs fell, an earnings report published today reveals.
Earnings per share came to HUF 81 for the period. Revenue edged down 0.7% to HUF 87.7 bln. Direct cost of sales fell almost 3% to HUF 32.1 bln, widening Richterʼs margin and lifting gross profit 0.6% to HUF 55.5 bln.
The first-quarter net income of Hungarian drugmaker Gedeon Richter rose 61% to HUF 15 bln from the same period a year earlier as costs fell, an earnings report published today reveals.
Other costs also fell: sales and marketing expenses were down 5.6% at HUF 25.7 bln and spending on R&D dropped 5.8% to HUF 10.9 bln. Operating profit climbed nearly 37% to HUF 13.9 bln.
Richter booked a HUF 2.3 bln financial gain in Q1, compared to a HUF 1.1 bln loss in the base period, though HUF 1.5 bln of the income was unrealized.
Capital expenditures, including payments for intangible assets, were down about 40% at HUF 3.3 bln.
In a breakdown of revenue by region, Richter said sales in Hungary rose 10.5% to HUF 10.7 bln, while sales in other European Union countries were practically flat at HUF 35.2 bln.
In Hungary, Richter had a market share of 5.3%, making it the third largest player. However, it was runner-up in the retail prescription drug segment, with 7.4% market share.
Sales in the CIS dropped more than 14% to HUF 27.8 bln. Sales in Russia fell about 12% to HUF 17.3 bln and sales in Ukraine plunged 49.5% to HUF 2.2 bln.
Richter noted that Russian sales, calculated in rubles, increased as it raised prices for about half of the drugs it sells there by around 25% during the period. It added that the ruble had weakened more than 45% to the euro year-on-year.
Sales in the U.S. were up about 32% at HUF 4.4 bln, sales in China increased 16.5% to HUF 3.7 bln and sales in Latin America climbed almost 22% to HUF 2.3 bln.
Richter had total assets of HUF 739.5 bln at the end of March, up 2.7% from the end of last year. Net assets rose 4.7% to HUF 587.9 bln during the period.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.